Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA 2072249 C · Owner: Mitsubishi Kasei Corporation · Inventors: Nagaike, Kazuhiro; Tagawa, Toshiaki; Hirakawa, Yoko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anticancer agent or toxin is also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 24, 1992 and granted June 17, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 24, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 24, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.